Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02432911Not ApplicableUnknown

Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old

Role: lead

NCT02432872Not ApplicableUnknown

Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years

Role: lead

NCT01633099Phase 3Unknown

Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients

Role: lead

All 3 trials loaded